Can hospital superbugs chew up stents and implants? Here's what a new study says
A dangerous hospital-acquired bacteria can digest and live on plastics present in sutures, stents, wound dressings and implants in your body. Researchers from UK's Brunel University also found that when the bacteria used plastics as its food source, it led to the formation of more biofilms — barriers that can protect the pathogen from attacks by the immune system and antibiotics.
The finding means that bacteria, such as the one they studied, could degrade medical implants, lead to infections at the site of the implant and cause infections that are harder to treat.
What did the researchers find?
There are bacteria in the environment that have developed the capacity to break down different types of plastics. So researchers wanted to see whether bacteria that cause infections in humans could also lead to such degradation within the body.
For the study, scientists looked for different pathogens with genes that could potentially produce enzymes similar to the ones that environmental bacteria use to degrade plastics. While they found several hits, they selected a Pseudomonas aeruginosa sample that came from a patient's wound. They isolated an enzyme — which they named Pap1— that could digest a type of bio-degradable plastic frequently used in medical devices called polycaprolactone (PCL) plastic. The researchers found that the enzyme degraded 78 per cent of the plastic sample in just seven days.
Importantly, the researchers found that the bacteria were not only degrading the plastic, they were also using it as their carbon source — effectively eating it. 'This means we need to reconsider how pathogens exist in the hospital environment. Plastics, including plastic surfaces, could potentially be food for these bacteria. Pathogens with this ability could survive for longer in hospitals,' Dr Ronan McCarthy, author and professor of biomedical sciences at Brunel University, said in a release.
Why is this concerning?
This is concerning for several reasons: One, bacteria could live on in hospitals or within a patient even when there aren't any other nutrients present. Two, they could degrade medical devices that use plastics, leading to their failure. This could lead to a rethink of materials that should be used for medical devices. Three, researchers found that the plastic-digesting bacteria could cause more severe infections. The researchers further found that the bacteria were using the broken down plastic molecules to create biofilms (a matrix made of sugars, proteins, fats and DNA) that make pathogens more resistant and difficult to treat. Four, degrading medical devices would also mean that the pathogens would be able to create pits and niches within the human body, where it could be shielded from the immune system and antibiotics, again causing difficult-to-treat infections.
Are there other pathogens that could have this ability?
Researchers found that other pathogens like Streptococcus pneumoniae, Klebsiella pneumoniae and Acinetobacter baumannii, too, carried genes that could potentially create plastic-digesting enzymes. More studies are needed. Importantly, the researchers found that Pap1 enzyme was structurally similar to known enzymes that can degrade even more hardy plastics such as PET bottles.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
27-05-2025
- India Today
Antibiotic for deadly superbug behind hospital infections enters final trials
A new drug that could help combat one of the world's most dangerous drug-resistant bacteria is now entering its final stage of human trials. This potential breakthrough could help in the global fight against antibiotic pharmaceutical giant Roche announced on Monday that its experimental antibiotic, zosurabalpin, developed in collaboration with Harvard University, is moving into phase 3 final phase will test the drug on around 400 patients worldwide, focusing on its ability to treat infections caused by Acinetobacter baumannii, a bacteria known to cause severe hospital-acquired infections like pneumonia and Acinetobacter baumannii is a short, rod-shaped, gram-negative bacterium. Scientists call it an "opportunistic bacterial pathogen" as it affects people with weak immune systems, highly present in hospital baumannii has been recognised as an "urgent threat" by the US Centers for Disease Control and Prevention (CDC), and has become increasingly resistant to existing no new antibiotics targeting this superbug have been developed in over five decades. Swiss pharmaceutical giant Roche announced on Monday that its experimental antibiotic, zosurabalpin, developed in collaboration with Harvard University, is moving into phase 3 trials. () What sets zosurabalpin apart is that it works in a new way, using a mechanism that bacteria haven't yet found a way to resist. This fresh approach brings new optimism to a field where many treatments are failing due to antibiotic caused by drug-resistant bacteria are not only difficult to treat but also widespread. Globally, sepsis is estimated to cause 11 million deaths a year, while community-acquired pneumonia (CAP) kills 3 to 4 million people annually, especially among the elderly."Antimicrobial resistance is one of the biggest infectious disease challenges to public health. Our goal is to contribute new innovations to overcome this growing threat.',' said Michael Lobritz, Roche's global head of infectious diseases, told The Tsai, head of immunology and product development at Roche's US unit Genentech, added that Acinetobacter baumannii is present in every country. He added that the unique biology involved in developing zosurabalpin might even lead to future discoveries in the fight against other resistant phase 3 trial will compare the effects of zosurabalpin to current standard treatments, and if successful, the drug could be ready for approval by the end of this decade.
Time of India
22-05-2025
- Time of India
IIIT-Delhi, French researchers develop AI tool to outsmart drug-resistant superbugs
New Delhi: In a boost to scientific advancement aimed at curbing the global threat of drug-resistant infections, researchers from the Indraprastha Institute of Information Technology-Delhi ( IIIT-Delhi ) and France's Inria Saclay have developed an artificial intelligence (AI)-based system that can recommend effective combinations of existing antibiotics to fight superbugs . Superbugs are germs like bacteria and fungi that cause hard-to-treat infections. Most superbugs are bacteria that have developed antibiotic resistance - the ability to survive antibiotic medications. The project, jointly led by Professor Angshul Majumdar and Dr Emilie Chouzenoux, is part of a broader India-France research collaboration between Deep Light (Delhi) and CentraleSupelec, a French engineering school, said an official statement of IIIT-D. The team includes engineer Stuti Jain and graduate researchers Kriti Kumar and Sayantika Chatterjee, it added. "This is an excellent example of how AI and international collaboration can come together to solve real-world medical challenges and our method makes it possible to use existing knowledge more effectively and opens the door to smarter, faster responses to antimicrobial resistance (AMR)," Prof. Majumdar told PTI. AMR occurs when bacteria adapt to antibiotics, rendering them ineffective. Prof. Majumdar said the misuse of antibiotics, particularly in countries like India, is a major contributor to the crisis. "We often take antibiotics even for viral infections, which don't require them. Over time, bacteria evolve and adapt. As a result, even simple infections like urinary tract infections or wounds can become resistant to treatment," he added. The AI system that the team developed goes far beyond traditional rule-based models. It analyzes real-world clinical decisions from leading Indian hospitals and combines this with bacterial genome data and the chemical structure of antibiotics to recommend optimal treatment options. The system was successfully tested on multi-drug resistant strains like Klebsiella pneumoniae, Neisseria gonorrhoeae and Mycobacterium tuberculosis. Prof. Majumdar shared a harrowing case from AIIMS, Kalyani, where a young patient's artificial hip joint became infected and was unresponsive to even last-resort antibiotics. "It was a simple muscle infection, but it became untreatable. The patient from a poor family was left bedridden and without options," he said. "This is the reality of AMR - it can devastate lives even when the infection seems ordinary." The professor said the AI model offers combination therapy suggestions, mirroring how doctors treat advanced cases today. "Instead of recommending one antibiotic, our system can propose a cocktail of drugs based on the genome sequence of the bacteria," said Majumdar. "Doctors can ask for five or ten possible options for a specific strain and the AI suggests viable treatments," he added. While the model is currently focused on bacterial infections, it can be retrained to tackle viral infections or even lifestyle diseases like hypertension, where drug resistance is emerging. "Our core motivation was to address infectious diseases - a problem that plagues countries in Southeast Asia, Africa and Latin America far more than it does the West," said Majumdar. "There's less funding for this kind of work, but the impact is massive," he added. The team hopes that their model would eventually be embedded in hospital systems and public health frameworks, particularly in regions with limited access to advanced diagnostics. With AMR recognized as one of the most pressing global health threats of the 21st century, this AI-powered solution may offer doctors a timely, data-driven ally in the battle to preserve the effectiveness of antibiotics.
Indian Express
22-05-2025
- Indian Express
Can hospital superbugs chew up stents and implants? Here's what a new study says
A dangerous hospital-acquired bacteria can digest and live on plastics present in sutures, stents, wound dressings and implants in your body. Researchers from UK's Brunel University also found that when the bacteria used plastics as its food source, it led to the formation of more biofilms — barriers that can protect the pathogen from attacks by the immune system and antibiotics. The finding means that bacteria, such as the one they studied, could degrade medical implants, lead to infections at the site of the implant and cause infections that are harder to treat. What did the researchers find? There are bacteria in the environment that have developed the capacity to break down different types of plastics. So researchers wanted to see whether bacteria that cause infections in humans could also lead to such degradation within the body. For the study, scientists looked for different pathogens with genes that could potentially produce enzymes similar to the ones that environmental bacteria use to degrade plastics. While they found several hits, they selected a Pseudomonas aeruginosa sample that came from a patient's wound. They isolated an enzyme — which they named Pap1— that could digest a type of bio-degradable plastic frequently used in medical devices called polycaprolactone (PCL) plastic. The researchers found that the enzyme degraded 78 per cent of the plastic sample in just seven days. Importantly, the researchers found that the bacteria were not only degrading the plastic, they were also using it as their carbon source — effectively eating it. 'This means we need to reconsider how pathogens exist in the hospital environment. Plastics, including plastic surfaces, could potentially be food for these bacteria. Pathogens with this ability could survive for longer in hospitals,' Dr Ronan McCarthy, author and professor of biomedical sciences at Brunel University, said in a release. Why is this concerning? This is concerning for several reasons: One, bacteria could live on in hospitals or within a patient even when there aren't any other nutrients present. Two, they could degrade medical devices that use plastics, leading to their failure. This could lead to a rethink of materials that should be used for medical devices. Three, researchers found that the plastic-digesting bacteria could cause more severe infections. The researchers further found that the bacteria were using the broken down plastic molecules to create biofilms (a matrix made of sugars, proteins, fats and DNA) that make pathogens more resistant and difficult to treat. Four, degrading medical devices would also mean that the pathogens would be able to create pits and niches within the human body, where it could be shielded from the immune system and antibiotics, again causing difficult-to-treat infections. Are there other pathogens that could have this ability? Researchers found that other pathogens like Streptococcus pneumoniae, Klebsiella pneumoniae and Acinetobacter baumannii, too, carried genes that could potentially create plastic-digesting enzymes. More studies are needed. Importantly, the researchers found that Pap1 enzyme was structurally similar to known enzymes that can degrade even more hardy plastics such as PET bottles.
